Chenyang Wang1, Tania B Kaprealian1, John H Suh1, Charlotte D Kubicky1, Jeremy N Ciporen1, Yiyi Chen1, Jerry J Jaboin1. 1. UCLA Department of Radiation Oncology, Los Angeles, California; Cleveland Clinic Department of Radiation Oncology, Cleveland, Ohio; Oregon Health & Science University Department of Radiation Medicine, Portland, Oregon; Oregon Health & Science University Department of Neurosurgery, Center for Health & Healing, Portland, Oregon; Oregon Health & Science University Department of Public Health & Preventive Medicine, Portland, Oregon.
Abstract
BACKGROUND: Adjuvant radiotherapy (RT) after surgical resection of World Health Organization (WHO) grade II meningioma, also known as atypical meningioma (AM), is a topic of controversy. The purpose of this study is to compare overall survival (OS) with or without adjuvant RT after subtotal resection (STR) or gross total resection (GTR) in AM patients diagnosed according to the 2007 WHO classification. METHODS: The National Cancer Database was used to identify 2515 patients who were diagnosed with AM between 2009 and 2012 and underwent STR or GTR with or without adjuvant RT. Propensity score matching was first applied to balance covariates including age, year of diagnosis, sex, race, histology, and tumor size in STR or GTR cohorts stratified by adjuvant RT status. Multivariate regression according to the Cox proportional hazards model and Kaplan-Meier survival plots with log-rank test were then used to evaluate OS difference associated with adjuvant RT. RESULTS: GTR is associated with improved OS compared with STR. In the subgroup analysis, adjuvant RT in patients who underwent STR demonstrated significant association with improved OS compared with no adjuvant RT (adjusted hazard ratio [AHR] 0.590, P = .045); however, adjuvant RT is not associated with improved OS in patients who underwent GTR (AHR 1.093, P = .737). CONCLUSIONS: Despite the lack of consensus on whether adjuvant RT reduces recurrence after surgical resection of AM, our study observed significantly improved OS with adjuvant RT compared with no adjuvant RT after STR.
BACKGROUND: Adjuvant radiotherapy (RT) after surgical resection of World Health Organization (WHO) grade II meningioma, also known as atypical meningioma (AM), is a topic of controversy. The purpose of this study is to compare overall survival (OS) with or without adjuvant RT after subtotal resection (STR) or gross total resection (GTR) in AM patients diagnosed according to the 2007 WHO classification. METHODS: The National Cancer Database was used to identify 2515 patients who were diagnosed with AM between 2009 and 2012 and underwent STR or GTR with or without adjuvant RT. Propensity score matching was first applied to balance covariates including age, year of diagnosis, sex, race, histology, and tumor size in STR or GTR cohorts stratified by adjuvant RT status. Multivariate regression according to the Cox proportional hazards model and Kaplan-Meier survival plots with log-rank test were then used to evaluate OS difference associated with adjuvant RT. RESULTS: GTR is associated with improved OS compared with STR. In the subgroup analysis, adjuvant RT in patients who underwent STR demonstrated significant association with improved OS compared with no adjuvant RT (adjusted hazard ratio [AHR] 0.590, P = .045); however, adjuvant RT is not associated with improved OS in patients who underwent GTR (AHR 1.093, P = .737). CONCLUSIONS: Despite the lack of consensus on whether adjuvant RT reduces recurrence after surgical resection of AM, our study observed significantly improved OS with adjuvant RT compared with no adjuvant RT after STR.
Authors: F J Vernimmen; J K Harris; J A Wilson; R Melvill; B J Smit; J P Slabbert Journal: Int J Radiat Oncol Biol Phys Date: 2001-01-01 Impact factor: 7.038
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker Journal: Neurosurgery Date: 2009-01 Impact factor: 4.654
Authors: Ricardo J Komotar; J Bryan Iorgulescu; Daniel M S Raper; Eric C Holland; Kathryn Beal; Mark H Bilsky; Cameron W Brennan; Viviane Tabar; Jonathan H Sherman; Yoshiya Yamada; Philip H Gutin Journal: J Neurosurg Date: 2012-08-24 Impact factor: 5.115
Authors: Ayal A Aizer; Nils D Arvold; Paul Catalano; Elizabeth B Claus; Alexandra J Golby; Mark D Johnson; Ossama Al-Mefty; Patrick Y Wen; David A Reardon; Eudocia Q Lee; Lakshmi Nayak; Mikael L Rinne; Rameen Beroukhim; Stephanie E Weiss; Shakti H Ramkissoon; Malak Abedalthagafi; Sandro Santagata; Ian F Dunn; Brian M Alexander Journal: Neuro Oncol Date: 2014-06-02 Impact factor: 12.300
Authors: Ernest Barthélemy; Joshua Loewenstern; Neeraja Konuthula; Margaret Pain; Jordan Hall; Satish Govindaraj; Joshua Bederson; Raj K Shrivastava Journal: J Cancer Res Clin Oncol Date: 2018-03-02 Impact factor: 4.553
Authors: C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-29 Impact factor: 7.038
Authors: Kerstin A Kessel; Wolfgang Weber; Igor Yakushev; Hanna Fischer; Theresa Voglhuber; Christian Diehl; Christoph Straube; Claus Zimmer; Benedikt Wiestler; Jens Gempt; Bernhard Meyer; Stephanie E Combs Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-22 Impact factor: 9.236
Authors: Brandon S Imber; Brian Neal; Dana L Casey; Heba Darwish; Andrew L Lin; Oren Cahlon; Brian Chon; Henry Tsai; Eugen Hug; Yoshiya Yamada; T Jonathan Yang Journal: Int J Part Ther Date: 2019-05-01